31 May DOE’s Misuse of Bayh-Dole’s ‘Exceptional Circumstances’ Provision: How Uniform Patent Policies Slip Away
Joseph Allen
IPWatchdog, 5/26/2022 ...
News
26 May Using Bayh-Dole for cancer drug march-in rights is wrong
David Kappos
Law360, 5/25/2022 ...
26 May Prostate Drug Price Controls Come at Too High a Cost
Craig Garthwaite
RealClearPolicy, 5/26/2022 ...
25 Apr Blockbuster cancer drug developed by Bay Area biotech at center of drug-pricing ‘march-in’ rights controversy
Ron Leuty
San Francisco Business Times, 4/22/2022 ...
07 Apr US universities fight potential Biden move on drug patents
Paul Basken
Times Higher Education, 4/7/2022
...
07 Apr $150K Prostate Cancer Drug Draws New Attention to ‘March-In’ Rights
Jennifer Henderson
MedPage Today, 4/6/2022 ...
06 Apr Removing patent rights to lower drug costs is dangerous precedent
Walter G. Copan
Denver Post, 4/6/2022 ...
04 Apr A dubious way to lower drug prices
Richard Parrish
Albany Herald, 4/2/2022 ...
31 Mar Biden’s looming prescription drug pricing dilemma
Caitlin Owens
Axios, 3/31/2022
Also published in Axios Vitals ...
31 Mar Stolen innovation cuts out taxpayers
Stacey Campfield
The Tennessean, 3/31/2022
Also published in Yahoo News, the Knoxville News-Sentinel, and the Commercial Appeal ...